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Abbreviations: ASMI: appendicular skeletal muscle index; a-v: arterio-venous; BCAA: 26 
branched chain amino acids; BMI: body mass index; CD: Crohn’s disease; CDM: male CD; 27 
Con: controls; ConM: male controls; CRP: C-reactive protein; dom: dominant arm; EGTA: 28 
Ethyleneglycol-Bis-β-Aminoethylether Tetraacetate; FCP: faecal calprotectin; FFM: fat free 29 
mass; FM: fat mass; HBI: Harvey Bradshaw Index; IL-1β: Interleukin 1 beta; IL-6: 30 
Interleukin 6; IPAQ: international physical activity questionnaire; LBM: lean body mass; LM: 31 
lean mass; non-dom: non-dominant arm; REE: resting energy expenditure; RER: respiratory 32 
exchange ratio (volume CO2 expired / volume of O2 inspired); SDS: standard deviation score; 33 
TNFα: Tumor necrosis factor alpha; TBM: total body mass.34 
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ABSTRACT 35 
Background and Aims: An inability to respond to nutrition could be implicated in low 36 
muscle mass in Crohn’s disease. We aim to determine skeletal muscle metabolic response to 37 
feeding in Crohn’s disease and healthy volunteers. 38 
Methods: Twenty asymptomatic Crohn’s disease participants (15.6 ± 0.5 yrs; BMI 20.6 ± 0.9 39 
kg/m2); 9 with active disease (faecal calprotectin, 808 ± 225ug/g and C-reactive protein, 2.2 ± 40 
1.2 mg/dl), 11 in deep remission (faecal calprotectin, 61 ± 12ug/g and C-reactive protein, 0.3 41 
± 0.2 mg/dl) and 9 matched healthy volunteers (16.0±0.6 yrs; BMI 20.7±0.6 kg/m2) were 42 
recruited.  Participants had a dual energy X-ray absorptiometry scan, handgrip dynamometer 43 
test, wore a pedometer and completed a food diary. Arterialised hand and venous forearm 44 
blood samples were collected concurrently and brachial artery blood flow measured at 45 
baseline and every 20mins for 2hrs after the ingestion of a standardised liquid meal. Net 46 
balance of branched chain amino acids and glucose were derived.  47 
Results:  48 
Controls had a positive mean BCAA balance. CD participants had an initial anabolic response 49 
to the meal, with increasing BCAA balance between t=0 & t=20, but returned to negative by 50 
t=60. This was associated with reduced FFM z-scores in CD but not with insulin resistance or 51 
disease activity. Exploratory analyses suggest that negative postprandial BCAA response seen 52 
in CD is predominant in males (p=0.049), with associated lower appendicular muscle mass 53 
(p=0.034), higher muscle fatigue (p=0.014) and reduced protein intake (p=0.026).  54 
Conclusions: The inability to sustain a positive protein balance postprandially could provide 55 
an explanation for the reduced muscle mass seen in CD. Further mechanistic studies will be 56 
needed to confirm these findings.  57 
 58 
Keywords: Crohn’s disease; Inflammatory Bowel Disease; Nutrition; Sarcopenia. 59 
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INTRODUCTION 60 
In the era of biological therapy and rising obesity in the general population 1 malnutrition is 61 
less prevalent in paediatric Crohn’s disease (CD), though still an apparent complication in a 62 
substantial minority 2,3,4.  Many of these patients also have disproportionately lower skeletal 63 
muscle mass 5,6.  Reduced muscle mass is seen in active disease 7, persists in remission 8 and 64 
is negatively correlated with disease duration 9.  Low muscle mass has been linked to 65 
decreased muscle function 10,11,12, low bone mass and density 13,14, reduced physical activity 66 
14
, fatigue and impaired quality of life 15.  67 
Skeletal muscle mass is determined by the balance between muscle protein synthesis and 68 
breakdown, rates of which determine protein turnover.  Children in active disease a have high 69 
protein turnover 16.  However, whereas conventional medical treatments such as 70 
corticosteroids17, elemental diets 17 and biological therapies 18 reduce fasting protein 71 
breakdown, they also reduce fasting protein synthesis, resulting in no change in net fasting 72 
protein balance when patients are in remission. 73 
Protein synthesis is stimulated by protein nutrition, particularly the branched chain amino 74 
acids (BCAA).  Twelve weeks of elemental diet induce partial normalisation of muscle cross-75 
sectional area with no further change at 52 weeks even when patients are in remission 14.  76 
Once the inflammatory burden is reduced, patients in remission may still suffer from low 77 
muscle mass 8, despite receiving apparently adequate protein nutrition 16,19. 78 
This suggests that reduced muscle mass in active disease is driven by inflammation and a sub-79 
optimal muscle protein synthetic response to protein feeding, termed anabolic resistance 20 80 
that may persist in remission.  Anabolic resistance is thought to be the main driver of muscle 81 
loss in critical illness, ageing and disuse 21.   82 
We hypothesise that reduced muscle mass and function in paediatric CD patients could be 83 
associated with anabolic resistance. We aimed to measure skeletal muscle protein balance in a 84 
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cohort of paediatric CD patients and age- and BMI-matched controls in both the overnight-85 
fasted and fed states. 86 
 87 
MATERIALS AND METHODS 88 
Study population 89 
We aimed to recruit male and female, stable, asymptomatic CD outpatients (age 11-18 years). 90 
Relevant CD symptoms were measured through a Harvey Bradshaw index 22.  Patients were 91 
approached from Nottingham University Hospitals Trust and Birmingham Women’s and 92 
Children’s NHS Foundation Trust existing patient population.  Disease activity was 93 
quantified through C-reactive protein (CRP), faecal calprotectin (FCP) and ileocolonoscopy 94 
or magnetic resonance imaging (MRI).  Active disease was defined as CRP >5mg/dl or FCP 95 
>250µg/g or the presence of ulceration at ileocolonoscopy or MRI scan.  In the absence of 96 
these findings patients were classed as in deep remission.  Any CD-related medication apart 97 
from corticosteroids within 3 months prior to recruitment was permitted.  Age-, gender- and 98 
BMI-matched healthy volunteers were recruited through advertisements at both institutions, 99 
through local press, and social media posts to parents.  All potential participants were given 100 
comprehensive written and verbal explanations of the study before giving written informed 101 
consent (parental consent at ≤15yrs) and were free to withdraw at any time.  Participants 102 
completed a general health questionnaire and underwent a short medical screening prior to 103 
participation.  The study was approved by the Health Research Authority (15/WM/0285) on 104 
the 26th July 2016 with the study conforming to the recognised standards of the Declaration 105 
of Helsinki.  106 
Outcome Measures 107 
The primary outcome was forearm skeletal muscle protein net balance under fasted and fed 108 
conditions.  Secondary outcomes were; forearm skeletal muscle glucose net balance; forearm 109 
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and whole body insulin sensitivity; resting and fed metabolic rate, daily physical activity; 110 
forearm muscle isometric strength and fatigability; appendicular lean mass (LM) and 111 
appendicular skeletal muscle index (ASMI); daily energy intake and dietary macronutrient 112 
composition; and markers of active disease (interleukin (IL)-1β, IL-6, TNFα, CRP and FCP). 113 
We investigated the effect of gender and disease activity on the primary outcome in an 114 
exploratory sub-analysis.  115 
Differences between arterialised venous and venous concentrations (a-v difference) of BCAA, 116 
and glucose, multiplied by brachial artery blood flow and corrected for forearm lean mass 117 
were used to determine the net balance of these nutrients across the forearm under fasted and 118 
fed conditions.  Positive values indicated net tissue uptake, whereas negative values indicated 119 
net release of nutrients.  The following equation was used for a given nutrient (N): 120 
Net balance of N (µmol/min/100g of forearm lean mass) = {Blood flow (ml/min) x 121 
([N]arterialised – [N]venous (mmol/L or µmol/L)}/1000 (not for glucose)/ {lean mass (g) x 122 
100}. 123 
Lean mass (LM) was measured by Dual-energy X-ray absorptiometry (DEXA) (Luna 124 
Prodigy, GE Healthcare).  The Matsuda index was used as an index of whole body insulin 125 
sensitivity 23,24, with a lower index indicating a higher level of insulin resistance.  Muscle 126 
strength measurements were standardized for muscle size, as well as for height and age, using 127 
the method developed by Rauch et.al 25, to facilitate comparison.  Appendicular LM (sum of 128 
lean mass in the limbs measured by DEXA) and ASMI (appendicular lean mass (kg) / height 129 
(m)2) were calculated to give more precise indices of skeletal muscle mass than total lean 130 
mass alone.  131 
Experimental protocol 132 
Participants reported to the laboratory at 0800, following an overnight fast, having abstained 133 
from strenuous exercise for the previous 48 hours.  On arrival, their body composition was 134 
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assessed by DEXA.  Body mass, whole body, and regional body composition and body mass 135 
index were calculated.  Subsequently, participants were asked to rest in a semi-supine position 136 
on a bed while a cannula was inserted in a retrograde fashion into a superficial vein on the 137 
dorsal surface of the dominant hand.  This hand was kept in a hand-warming unit (air 138 
temperature 55°C) to arterialize the venous drainage of the hand 26.  A second cannula was 139 
placed in an antecubital vein in the non-dominant forearm.  Both these cannulas were used for 140 
blood sampling.  After baseline blood samples, and measurements of brachial artery blood 141 
flow (in the non-dominant arm), as measured by Doppler ultrasound (Toshiba Aplio 300), and 142 
resting energy expenditure by indirect calorimetry (Cosmed, Italy), all participants ingested a 143 
220ml bottle of Ensure plus nutrition shake (t = 0).  This meal provided 330kcal, consisting of 144 
30% of energy as fat (11g), 53% of energy as carbohydrates (44g), and 17% of energy as 145 
protein (14g).  This meal composition mirrors dietary recommendations and specifically the 146 
protein content equates to 32% of the daily protein requirements of the CD subjects (0.75g/kg 147 
bw).  148 
Arterialized-venous (2 ml) and venous (2 ml) blood were obtained concurrently from the 149 
heated hand vein and antecubital vein along with brachial artery blood flow measurements at t 150 
= 0 and every 20 minutes thereafter for 2 hours, so that forearm muscle net balance of amino 151 
acids and glucose could be calculated in the fasted and fed states.  At t = 100 a final indirect 152 
calorimetry was performed providing resting energy expenditure (REE) and respiratory 153 
exchange ratio (RER) to compare with fasting levels.  154 
At the end of the 2-hour postprandial period, an assessment of forearm muscle function was 155 
undertaken.  Participants performed 12 maximal static voluntary contractions using a 156 
dynamometer (MIE medical research Ltd. UK), with both dominant and non-dominant arms.  157 
The peak contraction was taken as maximal handgrip isometric strength (kg), usually 158 
achieved within the first 2-3 contractions.  Level of fatigue was derived from the difference in 159 
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peak strength and strength measured at the end of 12 maximal contractions (mean of the last 160 
3) 27. Participants were familiarised with the protocol during screening and the same trained 161 
operator both gave instructions and took measurements from all participants 28.  SDS 162 
(standard deviation scores) were calculated for height dependent and weight dependent 163 
forearm strength as previously shown 25. 164 
Blood metabolite, cytokine & hormone analysis 165 
Blood glucose levels were measured using Yellow Springs Instrument Analyzer, YSI, 2300 166 
STAT PLUS. Plasma separated from Ethyleneglycol-Bis-(β-Aminoethylether) Tetraacetate 167 
(EGTA) treated blood was analysed for BCAA concentrations by spectrophometric assay 29. 168 
Serum separated from arterialised blood was analysed for insulin concentration with an 169 
enzyme-linked immunosorbent assay (ELISA) technique (DRG diagnostics, Germany).  CRP 170 
was measured by ELISA at the Department of Clinical Chemistry, Queen’s Medical Centre, 171 
Nottingham, as part of the initial screening process or in baseline blood samples.  172 
Inflammatory cytokines tumour necrosis factor (TNF)α; interleukin (IL)-6; IL-1β, and 173 
bioavailable testosterone, were measured in baseline (over-night fasted) arterialized plasma 174 
samples by colorimetric ELISA (R&D systems, Minneapolis, US) according to 175 
manufacturer’s instructions.   176 
Assessment of physical activity, habitual dietary intake & anthropometrics 177 
Step counts measured using a pedometer (Omron, Kyoto, Japan) for 3-days in advance of the 178 
study visit and self-reported levels of physical activity, using short form International 179 
Physical Activity Questionnaire (IPAQ) 30 were used to assess habitual physical activity 180 
levels.  Routine energy intake was measured using a 3-day paper-based food diary completed 181 
by participants in the days preceding their study visit (1 weekend day and 2 week days).  182 
Great care was taken in briefing participants, checking diaries during the study visit and the 183 
same operator analysed all the diaries using Nutritics software (Dublin, Ireland) in an effort to 184 
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minimise inaccuracy.  Anthropometrics were collected by a single investigator using a 185 
standard protocol and z-scores were calculated for height and BMI (WHO Growth Reference 186 
data for 5-19 year olds) and for fat mass (FM) and fat free mass (FFM)31. 187 
Statistical analyses  188 
The parametric or non-parametric nature of the data was determined with a Shapiro-Wilk test. 189 
Parametric data are presented as mean ± standard error of the mean (SEM) and non-190 
parametric as median plus interquartile range (IQR).  Parametric data has been examined 191 
using t-tests or where time is also a variable, two-way analysis of variance (experimental 192 
group x time).  Where data were not normally distributed, these were analysed using a Mann-193 
Whitney test.  Area under the curve (AUC) has also been calculated to illustrate glucose net 194 
uptake in response to feeding.  P value of <0.05 was considered significant.  Data analysis 195 
was undertaken with Prism software V.7.0 (La Jolla, San Diego, US) 196 
 197 
RESULTS 198 
Subject characteristics  199 
Twenty CD participants (15.6 ± 0.5 yrs; BMI 20.6 ± 0.9 kg/m2) were recruited (Table 1).  200 
Mean number of years since diagnosis was 4.3 ± 0.6.  All CD participants were asymptomatic 201 
with an HBI of < 4. Nine CD participants had evidence of disease activity with a mean FCP 202 
of 808 ± 225ug/g, mean CRP of 2.2 ± 1.2 mg/dl or evidence of ulceration at ileocolonoscopy 203 
or magnetic resonance enterography (MRE).  The other eleven CD participants were in deep 204 
remission with mean FCP of 61 ± 12ug/g and CRP of 0.3 ± 0.2 mg/dl and absence of disease 205 
activity at ileocolonoscopy or MRE.  Eleven participants were being treated with anti-TNF 206 
therapy (Adalimumab or Infliximab) while the rest were naïve to biological therapies.  Five 207 
CD participants had a history of intestinal resection for stricturing (n=3) or penetrating (n=2) 208 
disease behaviour.  See supplementary table for individual CD participant details.  Nine 209 
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healthy control (Con) participants (16.0 ± 0.6 years; BMI 20.7 ± 0.6 kg/m2) were recruited 210 
and matched to CD participants.  Although there were no significant differences in 211 
anthropometrics between groups 10% of CD patients had a BMI z-score of <-2.  It was not 212 
possible to cannulate two of the female CD participants, so for mechanistic studies in CD 213 
n=18.  All endoscopic or imaging investigations were undertaken as part of the patients’ 214 
standard care. 215 
Muscle physiology: protein and glucose metabolism 216 
Arterialized plasma BCAA (BCAA) peaked at t = 40 in response to feeding (time p<0.0001) 217 
(Figure 1A).  Con but not CD were in positive forearm muscle BCAA balance (Figure 1B), 218 
although both groups mounted an initial response to feeding (t = 0 to t = 20) (Figure 1C).  219 
Glucose a-v difference across the forearm increased in response to feeding, with this and 220 
glucose net uptake not different between CD and Con suggesting no skeletal muscle insulin 221 
resistance (Figures 2A & C).  222 
Body composition and muscle function 223 
There was a significant difference between Con and CD FFM z-scores (0.10 and -0.84 224 
respectively, p=0.015) but only trends towards a difference in LBM, appendicular LM and 225 
ASMI (Table 2).  All other body composition measures were comparable between Con and 226 
CD.  No differences were found in muscle strength or fatigue although there was a trend for 227 
CD to fatigue more than Con in the dominant arm. 228 
Whole body physiology:  insulin sensitivity and energy expenditure 229 
Arterialized blood glucose and serum insulin levels increased in both groups post-feeding (t = 230 
20) and peaked at t = 40, (time p<0.0001), (Figures 3A & B).  Glucose concentrations then 231 
dropped back, stabilizing above fasting levels by t = 60, whereas insulin continued to decline 232 
until t = 120.  CD response to feeding in terms of these parameters and Matsuda index was 233 
not different to Con and therefore no whole-body insulin resistance was detected (Figures 3A 234 
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- C).  REE and RER increased post-feeding (t = 0 vs. t = 20-120) in CD and Con (all p<0.05) 235 
with no differences between groups (Table 3).  236 
Cytokine analyses 237 
No differences in TNFα, IL-1β and IL-6 were observed between CD and Con groups although 238 
there was a trend for higher TNFα in CD (Table 1).  239 
Testosterone levels 240 
Testosterone levels were significantly higher in CD (median 9.0 ng/ml, IQR: 3.1-16.6) when 241 
compared to Con (1.8ng/ml, 1.4-8.2, p=0.031) (Table 1).  242 
Physical activity and diet 243 
Neither activity levels nor total energy intake differed between groups (Table 3).  244 
Gender and disease activity sub-analyses 245 
Male CD participants (CDM) n=11, were in overall negative BCAA balance, in contrast to 246 
the positive balance of male control participants (ConM) n=5, (p=0.049).  CDM also had 247 
lower levels of arterialised BCAA than ConM at baseline and post feeding (condition 248 
p=0.027).  CDM had a lower height for age when compared to ConM (z-scores -0.2 and 0.5 249 
respectively, p=0.021) and appendicular LM was 24% lower than in ConM (p=0.034).  CDM 250 
fatigued significantly more than ConM in the dominant arm (p=0.014).  Protein intake was 251 
lower in CDM (p=0.026) with 75 ± 5g/kg body mass/day reported in CDM and 105 ± 252 
15g/kg/day reported in ConM.  253 
There was a difference in skeletal muscle insulin sensitivity in active (n=9) versus deep 254 
remission (n=11).  In active disease forearm glucose net uptake was more than 2-fold greater 255 
than deep remission (p=0.036) implying skeletal muscle insulin resistance in CD in deep 256 
remission.  Serum insulin also peaked sooner in active disease, at 20 min, versus 40 mins in 257 
deep remission (interaction p=0.0014).  Active disease also had higher serum IL-6 levels than 258 
deep remission (median: 206 pg/ml, IQR: 83-390 vs. 41 pg/ml, 0-135, respectively; p=0.025).  259 
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There was however no difference in anabolic response between those in active disease and 260 
deep remission. 261 
 262 
DISCUSSION 263 
We hypothesised that the reduced muscle mass in CD could be driven through anabolic 264 
resistance of skeletal muscle to a mixed oral meal that may persist even when in clinical 265 
remission.  Con but not CD were in a positive net protein balance and this was associated 266 
with reduced FFM z-scores.  However, CD participants were able to mount an initial positive 267 
BCAA balance response to feeding and so may not be completely anabolically resistant as 268 
hypothesised.  Protein balance, and the ability to increase muscle protein mass, is also 269 
determined by muscle protein breakdown.  The overall neutral net balance observed in the 270 
current study may suggest that muscle protein synthesis and/or breakdown are affected.  Male 271 
CD participants had an overall negative protein balance, with associated lower appendicular 272 
LM, higher levels of muscle fatigue and reduced habitual dietary protein intake. Moreover, 273 
CD patients with active disease had similar net muscle protein balance, but a higher skeletal 274 
muscle glucose uptake, compared to those in deep remission.  These exploratory findings may 275 
imply that anabolic resistance plays a role in the aetiology of reduced LM in males 276 
irrespective of disease status. These findings will need to be validated in a larger cohort.  277 
Adolescent CD patients may therefore require more protein per meal compared to age-278 
matched controls in order to maintain a positive protein balance and muscle mass.  This is the 279 
first study to have investigated skeletal muscle protein balance in paediatric CD.  280 
Findings of reduced muscle mass in paediatric CD in remission are congruent with the 281 
majority of the literature 5,6,7,8.  Reduced muscle function has been previously found in 282 
paediatric CD patients with mild disease and in clinical remission 11. 283 
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CD participants in the current study still consumed more protein than recommended and their 284 
consumption was above National Diet and Nutrition Survey (NDNS) 2014-16 32 average 285 
values.  CD: 79g and NDNS: 67g (NDNS aged 11-18 and weighted to match our gender 286 
split).  However, a higher protein recommendation may be appropriate as a linear relationship 287 
between amino acid availability and protein balance holds true above current recommended 288 
intake levels because amino acids suppress muscle protein breakdown as well as stimulate 289 
protein synthesis33.  An overall increase in protein intake, rather than specific amino acid 290 
supplements, has recently been suggested to be most effective in both stimulating muscle 291 
protein synthesis and suppressing muscle protein breakdown 34.  Greater anabolic response to 292 
higher doses of protein in healthy adults has been shown to be largely due to the suppression 293 
of protein breakdown with only a small increase in protein synthesis 35.  Despite experimental 294 
studies indicating leucine is key in stimulating the mTOR pathway 36 chronic supplementation 295 
has not consistently produced positive results 34.  It has now been demonstrated that 296 
stimulation of muscle protein synthesis by protein ingestion is not solely due to leucine 37.  A 297 
study in CD adults showed that protein supplementation equivalent to a 25% increase in 298 
protein intake for 16 weeks improved LM; though no detail of protein turn-over was 299 
available38.  Our observation of a lower net protein balance in the face of adequate amino acid 300 
availability would further support the notion of an impaired anabolic response in CD.  301 
Testosterone levels were raised in CD.  This contrasts with previous studies that have reported 302 
both reduced androgens and delayed maturation in CD 39,40, though it is likely that these 303 
studies reported on total rather than bioavailable testosterone but did not specify.   304 
Insulin inhibits protein breakdown and has a permissive effect in stimulating protein synthesis 305 
via the Akt/mTOR signalling pathway 41,42.  Whole body insulin resistance has been found in 306 
CD patients with active disease 43 with TNFα being shown to reduce insulin sensitivity in 307 
humans 44.  In the present study skeletal muscle insulin sensitivity is similar between CD and 308 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
14 
Con as has been previously shown 45.  However skeletal muscle glucose uptake was higher in 309 
active disease vs. deep remission.  Although plasma TNFα levels were similar between these 310 
groups, plasma IL-6 was significantly higher in patients with active disease.  Chronically 311 
elevated levels of IL-6 have been implicated in insulin resistance and reduced skeletal muscle 312 
mass46.  Conversely acute administration of IL-6 has been found to increase glucose disposal 313 
47
.  It remains unclear why skeletal muscle insulin sensitivity may be higher in active disease 314 
vs. deep remission.  315 
Higher basal metabolic rate per FFM ratio and diet-induced thermogenesis have regularly 316 
been reported in CD, which could explain lower body mass48.  However, in accordance with 317 
the current study, several other studies in both paediatric CD49 and adults50,51 have found no 318 
relationship between the two. 319 
The association of reduced protein balance with reduced FFM z-scores in CD is a possible 320 
explanation as to why patients fail to gain muscle mass even when in remission.  CD may not 321 
be able to re-build muscle mass because they cannot maintain a positive protein balance in 322 
response to feeding.  In a study of young adult males with inflammatory bowel disease, a fifth 323 
of participants had significantly reduced muscle mass raising the possibility that these LM 324 
deficits persist into adulthood 52.  A longitudinal study would be needed to investigate this. 325 
The main limitation of this study is the relatively small sample size that will not allow 326 
detailed sub-analyses by disease activity and gender.  Moreover, it is cross-sectional and acts 327 
as a precursor to a larger prospective study.  Furthermore, although reduced serum Vitamin D 328 
has been implicated in reduced LM 53 values were unavailable in this cohort.  329 
A key strength was our use of the a-v balance technique giving a holistic view of the anabolic 330 
response and high temporal resolution.  The discovery that CD can respond to anabolic 331 
stimuli, albeit to a lesser extent than healthy controls, has important implications for 332 
treatment. 333 
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In conclusion, we have shown that reduced FFM z-scores in CD patients are associated with a 334 
reduced protein balance in response to feeding, thus providing a possible explanation for the 335 
persistence of low muscle mass in children regardless of disease activity.  Moreover, male CD 336 
participants were in overall negative protein balance with associated lower appendicular LM, 337 
height for age, fatigue in the dominant arm and protein intake.  This is an interesting 338 
preliminary observation that requires further elucidation.  A large prospective interventional 339 
study is warranted to confirm the effects of disease activity and gender, protein intake and 340 
exercise, with the aim of restoring muscle mass to healthy levels in children and young adult 341 
CD patients. 342 
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FIGURE LEGENDS 553 
Figure 1.  Indicators of protein metabolism in CD vs. Con:  arterialized plasma 554 
BCAA concentrations (A), mean BCAA net balance across the forearm 555 
standardized for forearm lean mass (B) and BCAA net balance across the forearm, 556 
over time, standardized for forearm lean mass (C).   557 
Values are means ± SEM.  Significant differences (p<0.05) & trends (p<0.1) are marked. 558 
BCAA=branched chain amino acids, CD=Crohn’s disease, Con=Control.  559 
SEM=standard error of the mean. 560 
Figure 2.  Skeletal muscle insulin sensitivity in CD vs. Con:  glucose arterio-venous 561 
difference across the forearm (A), brachial artery blood flow (B) and AUC glucose 562 
net uptake across the forearm standardized for forearm lean mass (C).  563 
Values are means ± SEM.  Significant differences (p<0.05) & trends (p<0.1) are marked. 564 
AUC=area under the curve, CD=Crohn’s disease, Con=Control, SEM=standard error 565 
of the mean. 566 
Figure 3.  Indicators of whole body insulin sensitivity in CD vs. Con: arterialized 567 
blood glucose concentrations (A), serum insulin (B) and Matsuda index (C).  568 
Values are means ± SEM.  Significant time effects are marked. CD=Crohn’s disease, 569 
Con=Control.  570 
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Table 1.  Subject characteristics of Control and Crohn’s disease patients 
  Con 
n=9 
CD 
n=20w / n=18v 
p value 
Age (yrs)w 16.0 ± 0.6 15.6 ± 0.5 n.s. 
Height (m) w 1.71 ± 0.05 1.66 ± 0.02 n.s. 
Height-for-age (z-scores) w 0.5 ± 0.4 0.1 ± 0.2 n.s. 
Weight (kg) w 60.7 ± 3.7 56.8 ± 2.7 n.s. 
BMI (kg/m2) w 20.7 ± 0.6 20.6 ± 0.9 n.s. 
BMI-for-age (z-scores) w 0.03 ± 0.27 -0.2 ± 0.3 n.s. 
Years since diagnosis w n/a 4.2 ± 0.6 n/a 
HBI w n/a 1 ± 0 n/a 
FCP (µg/g) w n/a 132 ± 41 n/a 
CRP (mg/dl) w <5 ± 0 2.6 ± 0.6 n.s. 
IL-1β (pg/ml)v 169 (37.5-517) 454 (30.5-1835) n.s. 
IL-6 (pg/ml) v 101 (50-335) 83 (28-287) n.s. 
TNFα (pg/ml) v  37 (0-111) 212 (0-661) p=0.078 
Testosterone (ng/ml) v  1.8 (1.4-8.2) 9.0 (3.1-16.6) p=0.031 
 
All values are means ± SEM except for non-parametric test results (cytokines & testosterone) 
where values are median and interquartile range and z-scores which were calculated for 
height-for-age and BMI-for-age using WHO standards.  Statistically significant differences 
(p<0.05) and trends (p<0.1) are listed and n.s. = no significant differences between groups. 
CD=Crohn’s disease, Con=Control.   
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Table 2.  Body composition and muscle function 
  Con  
n=9 
CD     
n=20w / n=18v  
p value 
Body compositionw      
FM (z-scores) 0.08 ± 0.37 0.90 ± 0.40 n.s. 
FFM (z-scores) 0.10 ± 0.44 -0.84 ± 0.15 p=0.015 
LBM (kg) 46.0 ± 4.5 39.3 ± 1.5 p=0.084 
Appendicular LM (kg) 22.9 ± 2.6 18.7 ± 0.8 p=0.057 
ASMI (kg/m2) 7.6 ± 0.4 6.8 ± 0.2 p=0.052 
Muscle functionv      
Fatigue (%) dom 18 ± 3 26 ± 2 p=0.061 
Fatigue (%) non-dom 21 ± 4 23 ± 2 n.s. 
Strength dom (kg/kg forearm LM) 23.8 ± 1.3 25.6 ± 1.5 n.s. 
Strength non-dom (kg/kg forearm LM) 23.9 ± 1.1 24.3 ± 1.4 n.s. 
Age dependent FS SDS dom -1.41 ± 0.35 -1.50 ± 0.22 n.s. 
Age dependent FS SDS non-dom -1.62 ± 0.31 -1.90 ± 0.21 n.s. 
Height dependent FS SDS dom -1.13 ± 0.35 -0.93 ± 0.34 n.s. 
Height dependent FS SDS non-dom -1.36 ± 0.33 -1.37 ± 0.36 n.s. 
 
All values are means ± SEM except standard deviation scores (SDS) calculated for height and 
age dependent strength (see methods) and z-scores calculated for FM & FMM using age and 
sex appropriate reference data (see methods).  Statistically significant differences (p<0.05) 
and trends (p<0.1) are listed and n.s. = no significant differences between groups. 
CD=Crohn’s disease, Con=Control, FS=forearm strength, dom=dominant arm, non-dom=non 
dominant arm.  
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Table 3.  Energy intake & energy expenditure 
  Con  
n=9 
CD     
n=20w / n=18v  
p value 
Energy intakew      
Energy intake (kJ/day) 9124 ± 1081 8333 ± 512 n.s. 
Protein intake (kJ/day) 1531 ± 173 1350 ± 93 n.s. 
Protein intake (g/day) 90 ± 10 79 ± 5 n.s. 
Recommended protein intake (g/day) 46 ± 3 43 ± 2 n.s. 
Indirect calorimetryv      
REE - fasted (kJ/hr/kgLBM) 6.1 ± 0.3 5.9 ± 0.4 n.s. 
REE - post-feeding (kJ/hr/kgLBM) 6.5 ± 0.3* 6.0 ± 0.4* n.s. 
RER – fasted 0.81 ± 0.02 0.76 ± 0.05 n.s. 
RER - post-feeding 0.87 ± 0.02* 0.80 ± 0.05* n.s. 
Physical Activityw      
Pedometer (no of steps/day) 8056 ± 849 7831 ± 725 n.s. 
IPAQ (total MET-mins/week) 6196 ± 2158 4443 ± 994 n.s. 
 
All values are means ± SEM.  Statistically significant differences between fed and fasted 
states in both groups are marked *=p<0.05.  n.s. = no significant differences between groups. 
CD=Crohn’s disease, Con=Control. 
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Highlights 
• A positive skeletal muscle protein balance is only seen in healthy controls 
• Neutral protein balance and reduced FFM z-scores in CD 
• No other differences in body composition or muscle physiology between CD 
& control 
• Negative protein balance, lower muscle mass and function in male CD 
